News Focus
News Focus
icon url

DewDiligence

01/01/15 2:35 PM

#185341 RE: iwfal #185336

BMY’s silence regarding plans for its 3-DAA regimen (#msg-108536151) suggests that BMY may not concur with Kolchinski’s “good enough” thesis for late-to-market HCV regimens.